Home / Articles / Patient safety

Regulation

Botulism after botulinum toxin: the medicolegal fault lines

In 2025, 41 people in England developed botulism after cosmetic botulinum toxin injections, and in 2026 the MHRA strengthened its warnings. Here is what the outbreak and the new rules mean for anyone who prescribes or injects toxin.

Medicolegal Chambers article cover: botulism after botulinum toxin and the unlicensed product risk
In this article

    In the summer of 2025 a treatment that is often described as routine produced one of the most serious clusters of harm UK aesthetic practice has seen. The UK Health Security Agency (UKHSA) investigated dozens of people who developed botulism after cosmetic botulinum toxin injections, several of whom needed hospital care and respiratory support. A year later, in July 2026, the medicines regulator strengthened the warnings that sit on every botulinum toxin product and set out what it expects clinicians to do. The combination of a real outbreak and a formal regulatory response changes the standard that a prescriber or injector will be measured against if a patient is harmed.

    This article is written for everyone who prescribes or administers botulinum toxin, or who runs a clinic where it is used: aesthetic doctors, dentists, nurse and pharmacist prescribers, GPs and private doctors who have moved into cosmetic work, and the clinic owners and registered managers who buy the product and write the protocols. It explains what happened, what the MHRA has changed, and what a defensible clinic should now be able to show.

    What happened in the 2025 botulism outbreak

    UKHSA first reported the outbreak on 18 July 2025 and updated the figures on 7 August 2025. By that point there were 41 clinically confirmed cases of iatrogenic botulism, meaning botulism caused by medical treatment, reported between 4 June and 6 August 2025. Cases were identified in the North East, the East Midlands, the East of England, the North West, and Yorkshire and the Humber. One of the reactions UKHSA described was breathing difficulty requiring respiratory support. The agency said the evidence so far suggested the use of an unlicensed product, and advised clinicians to consider botulism in anyone who became unwell after a recent aesthetic procedure, because treatment can include giving antitoxin.

    A detailed case-control study of the North East cluster, published in Eurosurveillance on 2 October 2025, found that people who developed botulism were significantly more likely to have received an unlicensed product, with a p value below 0.001. When investigators tested a seized product, they found a potency of 370 units per vial against the 200 units stated on its label. In other words, the vial held almost twice the toxin it claimed to, which makes the dose a patient actually received impossible to know. The study also found that cases were more likely to have attended two specific practitioners, and its authors concluded that stronger regulation of cosmetic procedures is needed, a risk they said is made worse by the availability of unlicensed products.

    SEIZED UNLICENSED VIAL What the label said, and what the laboratory found Label 200 units Measured 370 units ABOVE THE LABEL BY 85 per cent An unlicensed product can hold far more toxin than it claims, so the delivered dose cannot be known. SEIZED UNLICENSED VIAL Label against laboratory result Label 200 units Measured 370 units, 85 per cent above the label THE PROBLEM The delivered dose cannot be known
    When a seized unlicensed vial was tested, its potency was 85 per cent above the label, so no one could know the dose a patient had received.

    What the MHRA has changed

    On 15 July 2026 the MHRA announced that it was strengthening the safety warnings for all botulinum toxin type A products, and it updated that announcement on 19 October 2026. In its Drug Safety Update of 30 July 2026 the agency confirmed that the product information, including the patient information leaflet, is being updated to include a warning of iatrogenic botulism. The Drug Safety Update describes botulism as rare but potentially life threatening, with symptoms that can take up to four weeks to appear.

    The advice to clinicians is specific. Prescribers should check that the botulinum toxin product is authorised for use, and should follow the product-specific guidance in the product information for administration, dose and indication. The agency lists risk factors that should inform patient selection, including underlying disorders that may predispose a patient, use of high doses, off-label use, administration into an unapproved site, and counterfeit or unauthorised products. Anyone who directs another person to administer the product, including a cosmetic practitioner, should make sure they follow the prescription and are familiar with the update. The MHRA also reminded clinicians to counsel patients on the symptoms, which it lists as severe drooping of the upper eyelids, difficulty breathing, slurred speech and difficulty swallowing, and to tell them that this is a medical emergency for which they should seek immediate help. Suspected side effects should be reported through the Yellow Card scheme, and the MHRA has said its Criminal Enforcement Unit has launched several investigations into unlicensed botulinum toxin products.

    Check your understanding

    A practitioner is offered toxin at a large discount through a social media seller, with no UK authorisation details. A colleague says it is the same molecule, so the saving is worth it. What does the MHRA advice support?

    The 2025 outbreak was linked to an unlicensed product, and a seized vial was found to hold 85 per cent more toxin than its label stated. The MHRA advises prescribers to check that the product is authorised for use in the UK and warns that products obtained outside regulated supply chains do not meet UK safety and quality standards. Price is not a defence, and the prescriber who uses an unauthorised product carries the regulatory and clinical risk.

    Why unlicensed product is a medicolegal fault line

    The point that turns a safety warning into a medicolegal issue is accountability. A clinician who prescribes or administers a medicine takes responsibility for that decision, and that responsibility does not transfer to the supplier. If a patient is harmed by a product that was never authorised for use in the UK, the questions that follow are about the clinician's choice to use it: where it came from, why it was chosen, and whether the patient was told. An unlicensed product also removes the one thing a prescriber relies on, which is a known potency, as the seized vial at 370 units against a labelled 200 shows. Off-label use and injection into an unapproved site are listed by the MHRA as further risk factors, so a clinician who departs from the authorised indication should be able to explain and record the clinical reason for doing so.

    This is also where the clinical record earns its place. The provenance of the product, its authorisation status, the batch, the dose and the site are not administrative details. They are the evidence that a treatment was given responsibly, and their absence is difficult to defend. Our analysis of why aesthetic claims are so often lost on paperwork sets out the same pattern in complaints that do not involve botulism: the care may have been reasonable, but the record could not show it.

    WHAT THE RECORD SHOWS Authorised product confirmed Batch and dose recorded Examined before prescribing Botulism risk discussed Safety-netting given Thedefence
    Five lines in the record that answer a botulism complaint before it is made.

    Does the GMC still allow remote prescribing for toxin?

    No. The GMC's guidance on cosmetic interventions is explicit. At paragraph 11 it states that you must carry out a physical examination of patients before prescribing injectable cosmetic medicines, and that you must not prescribe these medicines by telephone, video link, online, or at the request of others for patients you have not examined. This has been the position for some years, and it applies whether or not a face-to-face assessment feels convenient. The regulators for nurses, pharmacists and dentists take materially the same view of safe prescribing in cosmetic practice, so a clinician in any of those professions who prescribes toxin for a patient they have not assessed is prescribing outside the expected standard.

    Responsibility is the second half of the rule. The GMC guidance says that where consent is needed it is your responsibility to discuss it with the patient and that you must not delegate that responsibility, and that a clinician who delegates administration remains responsible for the overall management of the patient and must be satisfied that the person providing care has the appropriate qualifications, skills and experience. A prescriber who signs for toxin that someone else will inject, in a setting the prescriber never sees, is not discharged of responsibility by the arrangement. The 2025 outbreak is a reminder of how that plays out, because UKHSA found that many of the cases had been treated in practitioners' homes, salons or patients' homes rather than in regulated clinical settings.

    Common assumptions

    Tap each card to compare the assumption with the rule.

    What botulism consent now has to cover

    Consent in this area is governed by the standard set in Montgomery v Lanarkshire Health Board and refined in McCulloch v Forth Valley Health Board: a patient must be told about the material risks of the proposed treatment and the reasonable alternatives, where a risk is material if a reasonable person in the patient's position would attach significance to it. A rare but serious complication can be material, and the test does not turn on how common the risk is alone. Once the national regulator has issued a formal warning that iatrogenic botulism is a risk of botulinum toxin, and has required that warning to be added to the product information, it is difficult to argue that a reasonable patient would not want to know about it. The practical consequence is that a botulism risk discussion now belongs in the consent for toxin, recorded in terms the patient understood, including the unusual feature that symptoms may appear days or weeks later. Our botulinum toxin consent guidance sets out the wider risk discussion these treatments require.

    The same logic reaches the consultation itself. A patient who is told that the product is authorised, that the clinician has examined them, and that there is a small risk of a serious delayed reaction with clear warning signs, is a patient who has been treated to the standard the MHRA and the GMC now describe. A patient who is simply handed a form is not. For clinics that want an independent view of where their consent and records currently stand, our consent audit looks at exactly these points, and the free Medicolegal Readiness Score gives a quick sense of the gaps in about five minutes.

    Recognising and responding to a suspected case

    Interactive

    If a patient reports symptoms after botulinum toxin

    Same day to four weeks

    Know the window

    The MHRA states that symptoms of iatrogenic botulism can appear from the same day up to four weeks after treatment. UKHSA found that in the 2025 cluster most cases began one to three days after injection, with ptosis or blurred vision in 68 per cent and difficulty swallowing in 57 per cent.

    On first contact

    Treat it as an emergency

    Drooping eyelids, slurred speech, difficulty swallowing or difficulty breathing after toxin are red flags. The MHRA describes these as a medical emergency, and the patient should seek immediate medical help through emergency services.

    As a clinician

    Escalate to public health

    UKHSA advises clinicians to discuss suspected cases urgently with the Colindale Duty Doctor and to notify their local Health Protection Team, because prompt antitoxin can be essential. A serum sample should be taken before antitoxin is given.

    Afterwards

    Report and preserve the record

    Report the suspected reaction through the Yellow Card scheme, and keep the product details, batch and your contemporaneous notes. Do not alter the record. If a complaint or claim is possible, contact your indemnity provider early.

    What to do in clinic now

    The outbreak and the strengthened warnings point to a small number of concrete steps that any clinic using botulinum toxin can take.

    1. Confirm and record authorisation and source. Use only botulinum toxin that is authorised for use in the UK, bought through the regulated supply chain, and record the product name, its authorisation status, the batch and the dose for every patient. Do not use product offered through social media sellers or other unregulated routes.
    2. Examine before you prescribe. Carry out a physical examination before prescribing, and do not prescribe by telephone, video link or online. If you prescribe for someone else to inject, satisfy yourself that they are competent and that the setting is appropriate, and keep your responsibility for the patient in view.
    3. Follow the product information. Keep to the authorised indication, dose and injection site, and be able to justify and record any clinical reason for departing from them. Be particularly cautious with high doses, which the MHRA lists as a risk factor.
    4. Put botulism into your consent. Add the risk of iatrogenic botulism to the consent discussion for toxin, explain that symptoms can appear up to four weeks later, and record that you did so in the patient's own terms.
    5. Give written safety-netting. Tell every patient which symptoms are an emergency, that they should seek immediate help if they appear, and how to contact you or a named suitably qualified person. Keep a copy in the record.
    6. Audit your toxin pathway. Review your procurement, your prescribing arrangements and your consent form against the points above, and fix the weakest link before you are asked about it. Our pages on clinical governance and the consent process describe what a defensible system looks like.

    Frequently asked questions

    UKHSA reported 41 clinically confirmed cases of iatrogenic botulism in England linked to cosmetic botulinum toxin injections between 4 June and 6 August 2025, across the North East, the East Midlands, the East of England, the North West, and Yorkshire and the Humber. Some patients needed respiratory support. The evidence so far pointed to the use of an unlicensed product.

    In its Drug Safety Update of 30 July 2026 the MHRA confirmed that botulinum toxin type A product information is being updated to include a warning of iatrogenic botulism. It advised prescribers to check the product is authorised, to follow the product information for dose and indication, and to counsel patients on the emergency symptoms. It has also said its Criminal Enforcement Unit is investigating unlicensed products.

    No. The GMC guidance on cosmetic interventions requires a physical examination before prescribing injectable cosmetic medicines, and states that you must not prescribe them by telephone, video link, online, or at the request of others for patients you have not examined. The same expectation of safe prescribing applies across the prescribing professions.

    The MHRA states that symptoms can take up to four weeks to appear. In the 2025 cluster UKHSA found that most cases began one to three days after injection, with a range from the same day to eleven days. Safety-netting advice therefore needs to cover the weeks after treatment, not only the first day.

    Treat it as a medical emergency. UKHSA advises clinicians to discuss suspected cases urgently with the Colindale Duty Doctor and to notify their local Health Protection Team, because prompt antitoxin can be essential, and to take a serum sample before antitoxin is given. Report the suspected reaction through the Yellow Card scheme, keep your contemporaneous record and the product details, and contact your indemnity provider. This article is general guidance and not advice on an individual case.

    Sources

    1. UK Health Security Agency. UKHSA issues warning over botulism. GOV.UK news story, first published 18 July 2025, updated 7 August 2025.
    2. Medicines and Healthcare products Regulatory Agency. Updated warnings for botulinum toxin products following rare cases of botulism. GOV.UK news story, 15 July 2026, updated 19 October 2026.
    3. Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Botulinum toxin type A products, updated warnings regarding risk of iatrogenic botulism, 30 July 2026.
    4. UK Health Security Agency authors. A local outbreak of iatrogenic botulism associated with cosmetic injections of botulinum neurotoxin-containing products, England, 2025. Eurosurveillance, volume 30, issue 39, 2 October 2025.
    5. General Medical Council. Guidance for doctors who offer cosmetic interventions, including paragraph 11 on prescribing injectable cosmetic medicines and the requirement for a physical examination.
    6. Montgomery v Lanarkshire Health Board [2015] UKSC 11, and McCulloch v Forth Valley Health Board [2023] UKSC 26, on material risks and reasonable alternatives in consent.
    About this article. This article is general education for healthcare professionals. It is not legal advice and does not create an advisory relationship. Medicolegal Chambers is an advisory consultancy, medical professional to medical professional. If you are dealing with a live complaint, claim, GMC, GDC, NMC or CQC matter, contact your indemnity provider or a solicitor first.

    Filed under: Regulation · Aesthetics · Governance

    Share: LinkedIn Email

    Keep reading

    Related articles

    High-risk cosmetic procedures: what the October 2026 consultation means for your clinic
    Regulation · 9 min read

    High-risk cosmetic procedures: what the October 2026 consultation means for your clinic

    CQC registration, doctors and independent prescribers only, and a list that reaches eyelid IPL, PRP and IV drips. What the proposals cover and what to do before January.

    Read the article →
    BDD screening before cosmetic procedures: what NICE now proposes
    Consent · 11 min read

    BDD screening before cosmetic procedures: what NICE now proposes

    The NICE draft on body dysmorphic disorder: the questions to ask, what to record, when to decline treatment and how it fits Montgomery.

    Read the article →
    Consent in UK aesthetic practice: the complete guide
    Consent · 15 min read

    Consent in UK aesthetic practice: the complete guide

    The whole subject in one place: what the law requires, who must take consent, capacity, time for reflection, the record and photographs. Our pillar guide.

    Read the article →

    Browse all articles →

    Clinical governance course

    Learn to govern your practice, with clinicians who sit on both sides.

    Clinical Governance Essentials for UK Aesthetic Practice is our live online course for qualified practitioners and clinic leads: twelve weekly one-hour sessions led by Professor Irfan Jeeva, working through the governance that keeps a clinic safe. The next intake opens soon. Register your interest and we will email you when enrolment and the dates are confirmed, with no obligation.

    Readiness Score